Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTICAL: Early Tacrolimus Cessation in Allogeneic HCT
NCT07302776Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tacrolimus + Wuzhi capsule in graft-versus-host disease (GVHD), sponsored by Stanford University. Primary endpoint: Safety and Feasibility of Early Tacrolimus Discontinuation at 180 days. Started Jul 2026; status: recruiting.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07302776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302776.